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Abstract
Background: Haematological malignancies (leukaemias, lymphomas and myeloma) are complex cancers that are
relatively common, affect all ages and have divergent outcomes. Although the symptom burden of these diseases
is comparable to other cancers, patients do not access specialist palliative care (SPC) services as often as those with
other cancers. To determine the reasons for this, we asked SPC practitioners about their perspectives regarding the
barriers and facilitators influencing haematology patient referrals.
Methods: We conducted a qualitative study, set within the United Kingdom’s (UK’s) Haematological Malignancy
Research Network (HMRN: www.hmrn.org), a population-based cohort in the North of England. In-depth, semi-
structured interviews were conducted with 20 SPC doctors and nurses working in hospital, community and hospice
settings between 2012 and 2014. Interviews were digitally audio-recorded, transcribed and analysed for thematic
content using the ‘Framework’ method.
Results: Study participants identified a range of barriers and facilitators influencing the referral of patients with
haematological malignancies to SPC services. Barriers included: the characteristics and pathways of haematological
malignancies; the close patient/haematology team relationship; lack of role clarity; late end of life discussions and
SPC referrals; policy issues; and organisational issues. The main facilitators identified were: establishment of inter-
disciplinary working patterns (co-working) and enhanced understanding of roles; timely discussions with patients
and early SPC referral; access to information platforms able to support information sharing; and use of indicators to
‘flag’ patients’ needs for SPC. Collaboration between haematology and SPC was perceived as beneficial and
desirable, and was said to be increasing over time.
Conclusions: This is the first UK study to explore SPC practitioners’ perceptions concerning haematology patient
referrals. Numerous factors were found to influence the likelihood of referral, some of which related to the
organisation and delivery of SPC services, so were amenable to change, and others relating to the complex and
unique characteristics and pathways of haematological cancers. Further research is needed to assess the extent to
which palliative care is provided by haematology doctors and nurses and other generalists and ways in which
clinical uncertainty could be used as a trigger, rather than a barrier, to referral.
Keywords: Cancer, Leukaemia, Lymphoma, Myeloma, Haematology, Specialist palliative care, End of life, Hospice,
Qualitative
* Correspondence: debra.howell@york.ac.uk
1Epidemiology & Cancer Statistics Group, University of York, York YO10 5DD,
UK
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
McCaughan et al. BMC Palliative Care  (2018) 17:33 
https://doi.org/10.1186/s12904-018-0289-1
Background
Haematological malignancies (leukaemias, lymphomas
and myeloma) are generally considered a complex group
of diseases that account for around one in ten of all can-
cers and affect all ages [1]. Characterised by remitting and
relapsing trajectories, unpredictable pathways and diver-
gent outcomes, these diseases range from indolent sub-
types that progress slowly over many years, to aggressive
conditions with poor prognoses. Although some disease
subtypes are considered incurable from diagnosis, new
and evolving therapies mean that some patients now have
relatively normal life spans; yet others continue to have
poor survival, despite intensive treatment [2, 3].
Patients with haematological cancers typically experi-
ence symptoms as a consequence of both their disease
and/or the side effects of treatment. These manifest phys-
ically and psychologically, and are comparable in number,
severity and distress to those experienced by patients with
other cancers [4–7]. Although the importance of good
symptom control and end of life care is widely recognised,
there is some evidence of unmet needs in settings outside
of the United Kingdom (UK) [6, 8, 9].
Specialist palliative care (SPC) is reported to have a
positive effect on quality of life for patients with
some cancers [10, 11], and early access to these ser-
vices is recommended alongside disease directed
treatment [12, 13]. For haematological malignancies,
evidence suggests that palliative care specialists can
optimise symptom management; facilitate more effect-
ive coping, accepting and planning for patients (and
family members) in dealing with prognostic uncer-
tainty; and act as a communication bridge between
the haematologist and the patients, particularly in sit-
uations where patients do not fully discuss their fears
and concerns with the haematology team [14]. Des-
pite this, research from the UK, United States (US)
and elsewhere, indicates that patients with these dis-
eases are not referred to SPC and hospice services as
often as people with other cancers [15–18]; and those
who access hospice care have poorer health at the time of
admission and shorter lengths of stay [19, 20]. These fac-
tors are often considered to reflect poor quality end of life
care [21].
Referral practices are increasingly the focus of inter-
national research (based mainly on reviews of patient re-
cords, but also some qualitative studies with
haematologists), which provides insights into reasons for
late or non-referral of patients with haematological ma-
lignancies [22–26]. A recent integrative systematic re-
view, for example, highlights reluctance on the part of
haematologists to refer to SPC services due to differing
treatment goals, prognostic difficulties, and preference
of haematology specialists to manage palliative care, as
barriers to referral [27]. However, knowledge of the
perspectives of SPC clinicians concerning barriers and
facilitators to referral is largely absent [20]. Our study,
the first of its kind in the UK, was designed to specific-
ally address this deficit, through interviews with SPC
doctors and nurses. The aim of the study was to capture
data that enhance understanding of factors that promote
or prevent the integration of palliative care and haema-
tology services.
Methods
Design
A qualitative approach, incorporating use of semi-
structured interviews to generate rich narratives, was
used to gain insight and understanding of how partici-
pants make sense of the topic under investigation [28].
Setting
The study was located within the UK’s Haematological
Malignancy Research Network (HMRN: www.hmrn.org),
a population-based cohort registering all patients newly
diagnosed with haematological malignancies across 14
hospitals in the Yorkshire and Humber region [1].
HMRN was established in 2004 by researchers and clini-
cians to provide infrastructure for an on-going
programme of work to generate evidence to improve the
clinical experiences of haematology patients and their
relatives.
Participants
A combination of purposive and snowball sampling was
used to identify SPC doctors and nurses experienced in
working with patients with haematological malignancies
across the study area. Potential interviewees were con-
tacted by post, email or telephone, and sent an informa-
tion leaflet, along with an invitation to participate in the
study. All of the 20 palliative care clinicians contacted
(including 6 SPC doctors and 14 nurses working in pri-
mary care, secondary care and hospice settings) agreed
to participate in the study.
Data collection
After obtaining written consent, in-depth, semi-
structured interviews (45–90 min) were conducted pri-
vately in participants’ workplaces between 2012 and
2014. With permission from the interviewee, these were
digitally audio-recorded, transcribed and anonymised. A
topic guide (Table 1), developed from existing literature
and the study team’s experiences, was used to guide in-
terviews, and data collection continued until no new in-
formation was forthcoming [29].
Data analysis
Transcripts were analysed for thematic content using
the ‘Framework’ method [30], whereby a coding scheme
McCaughan et al. BMC Palliative Care  (2018) 17:33 Page 2 of 11
and analytical framework were developed, drawing on
the topic guide, but incorporating new lines of inquiry
identified in the data. Coding and classification was sys-
tematic and inductive, involving data familiarisation
through reading/re-reading transcripts, coding tran-
scripts and developing analytical categories; followed by
identification of common patterns or ‘themes’, inter-
preted through seeking meaning, salience and connec-
tions. Negative or ‘deviant’ cases were actively sought in
the data [31], in order to develop and refine the analysis.
Data handling and charting, and comparison within and
between cases, was facilitated through use of electronic
spreadsheets. An overview of the data analysis process is
provided in Fig. 1, along with examples illustrating how
themes were developed.
Two researchers were involved in the data analysis (DM
and DH, both qualified nurses with extensive experience
of using qualitative methods in applied health services re-
search settings, and particularly haematology). DM read
all of the transcripts and carried out initial identification
and compilation of codes, while employing reflective notes
and memos. The notes and memos formed the basis of
regular discussions (DM and DH), initially to agree and
refine codes, and later to discuss emerging themes. Dis-
agreements during discussions offered insights that were
useful for refining data coding and interpretation [32]. An
experienced researcher (independent of the study) was
asked to assess the ‘fit’ of the coding scheme in relation to
two interviews [33] and confirmed that the strategy was
comprehensive and appropriate [34].
Ethical considerations
Ethical approval was obtained (Yorkshire and The Humber
Research Ethics Committee: 11/YH/0306). Participants
were informed they could withdraw from the study at any
time, and assurances were given concerning confidentiality
and anonymity.
Results
Study participants identified a range of barriers and fa-
cilitators influencing the referral of patients with haem-
atological malignancies to SPC services. Barriers
included: the characteristics and pathways of haemato-
logical malignancies; the patient/haematology team rela-
tionship; lack of role clarity; late end of life discussions
and SPC referrals; policy issues; and organisational
issues. The main facilitators identified were: establish-
ment of inter-disciplinary working patterns (co-working)
and role clarity; timely discussions with patients; access
to information platforms able to support information
sharing; and use of indicators to ‘flag’ patients’ needs for
SPC. Each of these is examined below, with illustrative
quotes:
Perceived Barriers
Characteristics and pathways of haematological
malignancies (Table 2)
Interviewees said that the most significant barrier to
haematology patients accessing SPC services was the un-
predictable trajectories and prognoses associated with
the diseases. One commonly cited example of this was
the propensity for unexpected deterioration and rapid
death, often when patients were being treated with in-
tensive chemotherapy, which resulted in insufficient
time to instigate an SPC referral.
Another frequently cited example related to the uncer-
tainty associated with the remitting/relapsing pathways
that characterise indolent blood cancers. These often in-
volve patients receiving intermittent life-prolonging
treatments (e.g. chemotherapy) and supportive care (e.g.
transfusions) over long periods of time, and often close
to the time of death, for disease control and to maximise
quality of life, with deterioration tending to occur
gradually.
Whilst such ongoing therapy was perceived as overly
‘aggressive’ by some, and a significant barrier to timely
SPC referral, others also described how salvage chemo-
therapy, delivered late in the pathway, could be given
due to the possibility of cure or remission, with haema-
tologists weighing up the feasibility of a ‘last ditch treat-
ment (to) pull a patient back from the brink’. Ongoing
treatment was also often said to be desired by patients
themselves, even in the face of diminishing response.
Collectively, the propensity for rapid deterioration, re-
mitting and relapsing pathways and treatment close to
death, resulted in indistinct transitions in the objectives
of care (curative or palliative). This was perceived as a
major difference between the pathways of haematology
patients and those with other cancers, the latter being
more predictable, with clearly demarcated junctures (e.g.
recognition that curative treatment had failed), at which
time care is often ‘handed over’ from oncology to pallia-
tive care specialists.
The patient/haematology team relationship (Table 3)
Participants described the close bonds that often exist
between patients and haematology staff, resulting from
frequent and/or prolonged contact from diagnosis on-
wards, which were said to engender high levels of pa-
tient trust in the clinicians’ expertise. While some
Table 1 Topic guide
1. Perspectives on referral of haematology patients to SPC services
2. Barriers and facilitators to SPC referral
3. Factors specific to the primary/secondary care interface
4. Issues specific to haematology compared to other conditions
5. Key changes that could promote collaboration
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interviewees perceived this positively, others considered
it a potential barrier to SPC referral, due to patients hav-
ing continuing ‘faith’ in ‘their’ haematologist to ‘come up
with’ a cure, or at least life-prolonging treatment. Hae-
matologists were considered reluctant to ‘let go’ of pa-
tients (e.g. to SPC staff/services), while active treatment
was on-going, and were thought to derive satisfaction
from caring for patients from diagnosis until death.
These close links were contrasted sharply with patients’
(and haematologists’) lack of familiarity with
community-based clinicians, including GPs, district
nurses and palliative care nurses.
Lack of role clarity (Table 4)
Some SPC clinicians believed haematology staff did not
always completely understand their role, perceiving it
mainly in relation to symptom control, while not always
fully recognising the wider remit, including the provision
of psychological and emotional support to patients and
family members. This was considered a barrier to pa-
tients’ accessing services, and was attributed to teams
Fig. 1 Analysis of data using the ‘Framework’ approach
Table 2 Characteristics and pathways of haematological
malignancies
Uncertainty and unpredictability
‘generally, oncology patients follow a kind of downwards steady decline…
whereas haematology patients just peak and trough, so it’s hard to predict
what somebody is going to do’ (SPC nurse 7)
‘I don’t think it’s quite as easy to predict a lot of the trajectories as it is for
some of the other malignancies…it’s not that simple for the
haematologists’ (SPC doctor 3)
Lack of clear transition points and treatment late in the pathway
‘other cancers, the oncologists will say “actually there’s no further treatment
we can offer at the moment because the side effects are going to
outweigh all the benefits now”…they will then discharge them into the
community, with the GP. Patients with haematological malignancies tend
to get treated and treated and treated…’ (SPC nurse 5)
‘haematologists give more aggressive treatments and do treat up until late
into a disease stage, but I think there just is this idea of potentially more to
gain’ (SPC doctor 4)
‘even when they’re [patients] on the brink of really being extremely poorly,
some weird and wonderful medicines can actually bring them back’ (SPC
doctor 3)
Patients’ desire to pursue treatment
‘there was a patient who, even with having a really detailed conversation
with a consultant and his family about the poor, poor prognostic outcome
of maybe fourth line chemotherapy…the patient wanted to, to take it’
(SPC nurse 14)
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and individuals working in isolation, with little face-to-
face contact, a situation particularly apparent with re-
spect to contact between members of the haematology
team and community healthcare providers. Referrals
were considered to occur less frequently from haematol-
ogy compared to other specialities and joint working
patterns were not normalised, with pressures on staffing
levels sometimes leading to existing co-working prac-
tices being curtailed.
Interviewees described some haematologists as taking
an ‘either/or’ approach to patient care, representing a
form of ‘dichotomised thinking’, with two sequential
stages in the illness trajectory, where active treatment
predominates during the first stage, and palliative care
in the second. This approach was thought to be associ-
ated with the view that palliative care was principally
terminal or end of life care, and was said to delay patient
access to SPC services.
Importantly, the degree to which patients with haem-
atological malignancies required SPC input was said to
be unclear, and it was suggested that end of life care
could, in some instances, be adequately met by members
of the haematology team, particularly with input from
clinical nurse specialists. The extent to which this oc-
curred was uncertain though, and participants noted
that specialist nurses, being usually located in busy clin-
ical environments, could have limited time to spend with
individual patients and their families.
Additionally, patients were said to lack awareness of
the palliative care services that could be available to
them, and to hold negative views towards resources such
as hospice care (‘somewhere you go to die’).
Late end of life discussions and SPC referrals (Table 5)
Introducing discussions with patients about likely treat-
ment and prognostic outcomes was said to be compli-
cated by the difficulties haematologists face in
identifying the ‘right’ time to begin conversations (due to
prognostic uncertainty); reluctance to broach the subject
until all treatment options had been exhausted; and try-
ing to avoid the feeling of ‘giving up’ on the patient. In-
dividual haematologists’ skills and confidence in
conducting discussions were perceived as variable, and
the nature and extent to which haematology specialist
nurses are involved in discussions was unclear to inter-
viewees. Patients were also sometimes said to be reluc-
tant to discuss end of life issues, often due to what were
Table 3 The patient/haematology team relationship
Close bonds and trust, and holistic care
‘they’ve [patients] got this relationship that’s gone on for years and years
with the [haematology] team and they know them well and feel safe and
secure with them’ (SPC nurse 3)
‘[haematologists] develop really close working relationships with these
patients, get to know them really well, so it doesn’t always seem easy or
appropriate to hand them over to palliative care’ (SPC doctor 3)
‘having built up that relationship over years there is the not wanting to let
go…not wanting to give up, there is the strong “let’s just try something
else” on the part of the clinicians and patients’ (SPC nurse 10)
‘they [patients] become very co-dependent with the staff on the ward and
the other way round, there is a very close personal relationship… and [hae-
matologists have] that satisfaction of providing all of the care, yeah, holistic
care, they’ve done everything for the patient, really.’ (SPC nurse 12)
Contact with community services
‘the majority of haematology patients tend to go back to the ward for any
care really. That seems to be their first port of call, rather than accessing
community services…they feel the haematology professionals understand
their condition more than the generalists in the community’ (SPC nurse 1)
Table 4 Lack of role clarity
Understanding of role(s) and relationship building
‘it’s understanding one another’s roles, it’s working together. When you
don’t get an opportunity to work together often, you don’t build trust and
understanding’ (SPC nurse 1)
Limited opportunities for haematologists and community palliative care
staff to build relationships
‘it’s not a face-to-face relationship [with haematologists] by us being removed
in the hospice and in the community’ (SPC doctor 6)
Dichotomised thinking: either active treatment or palliative care
‘I think in people’s minds still there is that dichotomy that you’re either having
active treatment or you’re having palliative treatment’ (SPC doctor 6)
Negative patient perceptions of hospice services
‘“Gosh, the Macmillan nurse is here, that means I’m going to die…”’ (SPC
nurse 14)
Table 5 Late end of life discussions and SPC referrals
Difficult discussions and having the skills/confidence to initiate them
‘“this chemotherapy has done nothing for you, and actually you are dying”,
that must be a really difficult conversation to have…so I think that
conversation is sometimes put off ’ (SPC nurse 11)
‘I think the [haematology] consultants struggle sometimes…you don’t
want to feel you are giving up on them [patients] some are better than
others in having discussions with patients’ (SPC nurse 14)
‘if those conversations haven’t been had… then you can’t even begin
to start to have the next conversations about preparing for dying’ (SPC
nurse 4)
‘with a lot of haematological malignancies a percentage of people can be
cured…so [end of life care is] not necessarily something you want to ask
at the very beginning when you’re embarking on what might be curative
treatment, so it’s quite difficult picking the right time to have those
conversations’ (SPC doctor 2)
Timing of SPC referral
‘the acute leukaemias… it’s [referral] very, very end stage, once the marrow
is completely failed…the ones we get nearest to are the people with
myeloma, where they tend to have lots of bone pain...so we tend to get
involved a bit earlier there…’ (SPC doctor 1)
‘by the time [of] the referral, he was imminently dying…that is really, really
difficult for us because you don’t have time to build up a relationship, that
trust… you often get involved in the very, very end stage. If we could get
earlier [referral], build those relationships up so we can explain to patients
and their families that we are able to support people at home, to put
packages of care to support them, so that they build trust, so they know
what contact numbers [to ring], so they don’t have to ring the
haematology ward’ (SPC nurse 1)
Patient reluctance to engage in conversations about end of life
‘some haematology patients choose not to know there is no more
treatment that they can have… they make a choice not to have this
conversation’ (SPC nurse 11)
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considered unrealistic expectations about treatment
outcomes.
Interviewees said that SPC referrals were often made
late in the pathway, after all treatment options had
failed, and when the patient was close to death. Mye-
loma patients with intractable pain were the recognized
exception, many of whom were said to be referred soon
after diagnosis. Late referrals were said to cause difficul-
ties, as patients could already be severely ill and rela-
tives/carers highly distressed at this time. Such
situations were said to leave SPC staff with little time to
establish trust and rapport, elicit end of life preferences
and coordinate care before the patient died. Younger pa-
tients in particular were described as disinclined to con-
sider SPC referral while receiving treatment, even in the
face of diminishing options.
Policy issues (Table 6)
National and local policies were perceived as potentially
impeding early access to SPC services for patients with
haematological malignancies, with participants citing
how specific criteria (such as the presence of complex
symptoms, irresolvable by the haematology team) were
often necessary before referral was considered justified.
Such criteria were cited as inappropriate for some pa-
tients with haematological cancers, as they negated re-
ferral of individuals without such difficulties, but who
could deteriorate unexpectedly and rapidly, and require
input at this time. In such circumstances, patients are
likely to be disadvantaged as, due to the limited time
available before death, they may not accrue the max-
imum benefits of SPC input. In this context, many inter-
viewees considered the unpredictable nature of
haematological cancers sufficient of itself to constitute
justifiable referral criteria.
Administration of life prolonging therapies (e.g. blood
product transfusions and antibiotics), on which many
patients depend, was said to conflict with some hospices’
admission criteria, although it was reported that this was
changing in some places. Improvements in the willing-
ness of these facilities to administer supportive therapies
was considered important if access to hospice services
was to be maximised.
Organisational issues (Table 7)
‘Fast track’ discharges
Short notice or ‘fast track’ hospital discharges, where pa-
tients were expected to die rapidly and wanted to be
transferred home, were considered particularly common
in patients with haematological malignancies. Such situ-
ations were said to pose significant challenges to the
timely co-ordination of multi-agency, community-based
nursing and palliative care services, and organisation of
the equipment required to facilitate the patient’s return
home. Most participants commented that this situation
was further complicated because General Practitioners
(GPs) had often ‘lost contact’ with patients (who were
managed largely in the hospital setting), so could be un-
aware of their changing prognosis. Participants under-
scored the importance of GPs receiving as much notice
as possible concerning impending patient discharge.
SPC input was also said to be limited by lack of avail-
able hospice beds at short notice and variations in the
availability of community palliative care services, which
were described as ‘patchy’ in some areas, with ‘round the
clock’ care being particularly difficult to access.
Information platforms
Existing technology was said to limit the sharing of in-
formation between disciplines (e.g. palliative care and
haematology) and settings (e.g. secondary and primary
care). SPC clinicians said that lack of a unified electronic
record meant that they were often unable to access de-
tails of conversations about prognosis, treatment cessa-
tion and end of life care that had taken place between
haematology staff and their patients and relatives, re-
quiring them to re-initiate such discussions. Incomplete
access to individual patient information was said to po-
tentially impede ‘joined up’ approaches to care, deter the
Table 6 Policy issues
Palliative care referral criteria
‘there is strict criteria for referral to specialist palliative care in the
community…she didn’t meet the criteria’ (SPC nurse 9)
Provision of blood products in hospice settings
‘some hospices will give blood products…we try and avoid giving them
out at weekends and during out of hours… every hospice I’ve worked at
has had a policy… that when you’re giving blood products you actually
need a doctor on site, in case of a reaction’ (SPC doctor 4)
‘the hospice is very much, much more able now to transfuse patients, even
with platelets which is much more helpful’ (SPC nurse 14)
Table 7 Organisational Issues
‘Fast-track’ discharge home or to the hospice
‘in haematology patients…can you get people home quick in a very fast
changing situation? If you’ve got lung cancer and somebody thinks they’re
starting to die, you often have a window to get people home, whereas
haematology… you might have a few hours’ (SPC doctor 6)
‘sometimes you can get a [hospice] bed the next day, sometimes you can
wait two weeks or more’ (SPC doctor 6)
Lack of GP involvement and impact on the provision of end of life care
‘some GPs, they have haematology patients and they are diagnosed and
they don’t see them for two years, three years and then suddenly there is
no more treatment for them, they’re discharged home and they’ve [GPs]
kind been out of the loop’ (SPC nurse 8)
‘if you’ve got to frequently come to hospital and see the doctors, you don’t
tend to find that they also frequently see their GP…so [patients] don’t have
the same relationships with the community support staff as some other
patients’ (SPC doctor 2)
Access to shared records
‘we’d only get the paper records from haematology anyway…so we don’t
really know if any advanced planning [had taken place]…so it’s a big void
there’ (SPC nurse 1)
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‘flagging up’ of patients approaching end of life, prevent
early identification of those likely to require SPC input,
and preclude preferred place of care/death being
achieved. Conversely, participants suggested that access
to a single record could lead to broader use of end of life
tools, such as the Gold Standard Framework.
Perceived Facilitators
Interdisciplinary working patterns (co-working) (Table 8)
Co-working was said to facilitate early access to pallia-
tive care specialist input, which could be delivered
alongside the haematology team either continuously (‘in
tandem’, ‘in parallel’) or intermittently (where clinicians
‘dip in and out’). The presence of palliative care special-
ists in haematology ward rounds, during multidisciplin-
ary team meetings and in clinics was viewed as a time-
efficient way for clinicians to contribute to haematology
patient care, whilst also providing the opportunity to
share expertise. The benefits of co-working were said to
be: joint assessment of patients’ needs; opportunities to
deliver specific interventions in response to changes; and
increased time to build rapport with patients and rela-
tives, consider quality of life issues, explore end of life
preferences and participate in advanced planning. Co-
working was also said to promote visibility and enhance
understanding of roles, factors interviewees considered
important in raising their profile and increasing referrals.
Co-location of haematology and palliative services was
said to foster closer working through regular informal
opportunities for inter-professional communication.
There was general consensus among the palliative care
specialists that their collaboration with haematology was
beneficial and desirable, and that it had increased in re-
cent years.
Timely discussions with patients and early SPC referral
(Table 9)
Early initiation of honest, frank conversations about
treatment and prognosis was viewed as a pre-requisite
for patient engagement in end of life discussions, ad-
vance planning and SPC referral. Participants suggested
that early introduction of SPC clinicians as integral
members of the care team facilitates a more positive
view amongst patients of their increasing involvement
towards the end of life, and provides patients (and their
family members) with increased opportunities for sup-
port (e.g. emotional and psychological support, as well
as more time to explore quality of life issues and end of
life preferences).
Access to information platforms able to support
information sharing (Table 10)
Shared access to information platforms used by haema-
tologists and other health care professionals (e.g. GPs)
was viewed by SPC clinicians as facilitative of patient
Table 8 Interdisciplinary working patterns (co-working)
Working ‘in tandem’ or intermittently
‘getting the palliative care professionals involved quite early, um, so that
you’ve got this nice long overlap between the haematology…and the
palliative care input so that eventually when somebody is discharged or
isn’t being followed up as regularly by the haematologists, they know they
are supported by the palliative care team already.’ (SPC doctor 4)
‘I think we can be involved…and then the patient changes, deteriorates, so
we go back in, we sort it out, we come out again…so we have sort of
several episodes of care within that journey of care, dependent on what
their needs are’ (SPC nurse 5)
Co-working and visibility
‘the palliative care team attend weekly MDTs, so communication is very
good’ (SPC nurse 3)
‘working in partnership with the [haematologists] helps… I think the ward
rounds, being that visible person in the ward round, where you can pre-
empt some things and then prompt them’ (SPC nurse 5)
‘our relationship is really good…we couldn’t go for a period to the ward
rounds and referral started to drop off…it’s about our visibility…if we’re
there it reminds them that actually they can ask our advice and referrals
go up, when we’ve got a high profile, referrals go up’ (SPC nurse 13)
‘the (haematology) consultants here, I have a very good working
relationship with them, and I know I can pick up the phone and say, “I’ve
seen your patient on the ward today and they’ve expressed these concerns”’
(SPC nurse 14)
‘now it’s a big thing, because referring on to palliative care means you’re
[patient] going to be dead in two days… whereas if you’re seen and
perceived to be working much closer together, as an integrated team
involved from earlier on… then it’s no big deal…’ (SPC doctor 1)
Co-location
‘we’re quite fortunate in that most of the haematologists are always down
this corridor so quite often they will actually pop into our office and talk to
us about patients…as well as the ward round, there is that informal
opportunity for talking about patients’ (SPC nurse 13)
Growing collaboration between palliative care and haematology
specialists
‘I have to say, in the past 10 years, communication [between teams] has
improved quite significantly…so that’s obviously been a change for the
better’ (SPC nurse 14)
‘we’ve [SPC nurses] got very close relationships with the haematology
wards…there’s a group of us who cover those wards so we’ve built up
relationships and they know who we are and they refer to us directly’ (SPC
nurse 14)
‘the more time we spend with the haematologists and the more
relationships that we build up, the more patients of theirs they refer to us
that we help, then the better the relationship gets. It’s all about relationship
building. We’re learning about their specialty as much as they’re learning
about us and it’s just about shared understanding I think…we have a joint
clinic once a week…influencing decision making patient by patient…you’re
seen as more as part of the team’ (SPC doctor 6)
Table 9 Timely discussions with patients and early SPC referral
Early initiation of honest, frank conversations
‘I think it’s about being honest with the patient… where they are with the
disease… what treatment, management or supportive options are
available to them, a little bit earlier’ (SPC nurse 5)
Benefits of early SPC referral
‘in the UK… there is this overlap… and the diagram of the model of care
really has palliative care involved almost from the outset… of an
ultimately untreatable condition, and increasingly involved towards the
end. And certainly.. I think that is something that needs to be adopted,
because there is nothing about the active management of a malignant
disease that stops palliative care teams getting involved’ (SPC doctor 4)
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referral, through improved communication across the
primary/secondary interface. It was also said to speed up
patient access to available palliative care services.
Use of indicators to ‘flag’ patients’ needs for SPC
(Table 11)
A means of identifying or ‘flagging’ individuals who
might soon require end of life care was highlighted as a
potential facilitator to the appropriate timing of SPC re-
ferral. Use of a ‘traffic light’ system or ‘Gold Standards’
approach was suggested, along with the development of
‘indicators’ or ‘triggers’, based on diminishing response
to treatment, which would signal when an SPC referral
should be considered.
Discussion
This is the first UK study to explore SPC doctors’ and
nurses’ perceptions about the referral of patients with
haematological cancers to their services. Our findings
overlap those arising from research conducted with hae-
matologists [22–24], thus confirming and complement-
ing these studies’ results. New insights we offer include
SPC clinicians’ perspectives that their role is not always
well understood by haematologists, as well as their per-
ceptions of the importance of co-location of services in
promoting and enhancing role clarity and closer working
patterns. Improvements such as shared access to infor-
mation platforms across the specialist disciplines and
different care settings were described by study SPC clini-
cians as fundamentally necessary to enhance patient re-
ferral and integrated care delivery. The need for
indicators or ‘triggers’ to promote early referral of haem-
atological patients identified in our study has previously
been reported in research from the US [26]; our UK
findings reinforce these earlier reports, signalling wide-
spread recognition of the requirement for further devel-
opments in this area.
Collaboration between disciplines was perceived as
beneficial and desirable, though was said to occur less
frequently than for patients with other cancers, with a
range of issues influencing the likelihood of referral. Bar-
riers largely related to the unique characteristics and
pathways of haematological malignancies. Uncertainty
(due to fluctuating trajectories, sudden deterioration and
death, “last ditch” attempts at salvage, and indistinct
transitions) was a significant barrier. Also important
were the close connections between patients and the
haematology team; late end of life discussions and SPC
referrals; organisational issues (such as distant relation-
ships with primary care and specialist palliative care
practitioners and limitations to information platforms);
lack of role clarity (perceived as “either/or”, curative or
palliative) approaches to treatment; and UK policy gov-
erning access to SPC services. Facilitators included early
referral to SPC services or co-working between disci-
plines from diagnosis; mutual understanding of roles;
timely, frank discussions about prognosis and treatment
cessation along with early SPC referral; access to IT plat-
forms able to support information sharing; and the use
of indicators to ‘flag’ patients requiring SPC input.
Current UK policy on commissioning palliative care
services distinguishes ‘core’ (generalist) from ‘special-
ist’ providers [35]; in our study, the former comprise
haematology staff, GPs and district nurses, and the
latter SPC practitioners in hospital, community or
hospice settings. The hospital palliative care special-
ists we interviewed described how the end of life
needs of haematology patients may be met by the
haematology team, and particularly the clinical nurse
specialists. Although we found the extent to which
this occurred unclear, another UK study has reported
that haematologists considered the delivery of ‘gener-
alist’ palliative care integral to their role, with special-
ist referrals being made only when they were unable
to meet patients’ needs themselves [23]. Without
knowledge of such patterns in care, however, it is dif-
ficult to determine whether perceptions of fewer SPC
referrals reflect unmet need, or whether these needs
are simply being met by others. In the UK, there is a
lack of clarity around this issue; and until more is
known, it is difficult to determine and quantify the
extent to which specialist interventions are required.
Whilst unclear transitions and difficulties in prognosti-
cation were considered significant barriers to the timeli-
ness of end of life discussions and palliative care
Table 10 Access to information platforms able to support
information sharing
‘we share records with a lot of the GPs and have access to the hospital
letters there, so all that information is available…it really helps, you can
access what the last things the haematologists have said were…I see this
as in a state of flux, something that is improving and something that is
very key’ (SPC doctor 4)
Table 11 Use of indicators to ‘flag’ patients’ needs for SPC
‘Flagging up’ patients’ needs for SPC
‘the palliative care register, they have the traffic light system…green is that
[patients] are ticking along very nicely, and they’re doing alright, amber is
that they’re rather slightly deteriorating but, you know, could go either way,
and red is that they are deteriorating’ (SPC doctor 2)
“we think this patient is in their last year” and “we think they should go on
your Gold Standards (Framework), so at least we would be flagging up to
the GP that this is the time to start considering these things” (SPC nurse 4)
Identification of ‘triggers’ signifying patients could benefit from SPC
referral
‘if the patient's response [to transfusions] is either not as good, or not
lasting as long, those should be the triggers that the disease is changing,
they need to start to broach the idea of palliative input…and to think
about involving the GP’ (SPC nurse 6)
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referrals, many interviewees considered such characteris-
tics should, in fact, act as triggers for advance planning.
Interestingly, this has also been suggested in the context
of chronic disease such as advanced heart failure, where
similar complexities are reported [36, 37]. Such uncer-
tainties were said to be a major difference between
haematological malignancy pathways and those of other
cancers. This was undoubtedly linked to the characteris-
tics and pathways of the former diseases, which do not
generally adhere to the traditional dichotomy of ‘cura-
tive’ and ‘palliative’ phases, with distinct delineation be-
tween the two states. Haematology subtypes may, for
example, be incurable from diagnosis but manageable
with intermittent or continuous chemotherapy, given
with ‘life-prolonging’ intent (often late in the pathways)
for disease control and to improve quality of life; or may
be curable but result in rapid, unexpected death (with-
out transition) due to haemorrhage or sepsis.
Where SPC input was warranted, late referrals were
found to be challenging, particularly if the patient’s pref-
erence was to die at home, and care systems and equip-
ment were required at short notice to facilitate this, but
contact with the primary care team had been lost. The
use of indicators or triggers to ‘flag up’ patients nearing
the end of life and possibly requiring SPC referral was
suggested as a means by which to address these issues,
and the use of such systems, including dynamic prog-
nostic tools, has been advocated by US oncologists [26].
Such interventions may, however, have little value in the
context of sudden and unexpected deterioration, with
the lack of key prognostic indicators, particularly for pa-
tients being treated less aggressively or with palliative in-
tent, being a further limitation [38].
Co-working with the haematology team (from diagno-
sis; concurrently or intermittently; regardless of symp-
toms or prognosis), or early palliative care referral, were
suggested as models by which late referrals could poten-
tially be ameliorated. Such ‘upstream’ integration, which
negates the need to identify the end of life phase, has
been suggested by others [14, 39–42], including the
World Health Organisation [43], who state that “pallia-
tive care is applicable early in the course of an illness, in
conjunction with other therapies that are intended to
prolong life”. This would enable patients receiving treat-
ment with curative intent, who may deteriorate sud-
denly, to begin to forge a relationship with the SPC team
prior to their input being required. Other ‘best practice’
models supporting integration of palliative care into
haematology settings also suggest early patient referral,
as well as a collaborative multi-disciplinary approach to
care [44]. Such models appear, however, to be at odds
with current UK commissioning guidance, which recom-
mends that ‘specialist’ provision should be restricted to
people with ‘unresolved complex needs that cannot be
met by the capability of the current team’ [35]. Limita-
tions may also be imposed by the additional resources
(e.g. adequate numbers of SPC staff ) likely to be re-
quired to meet this extended role and inconsistencies in
hospice policies regarding the administration of life-
supporting and prolonging therapies, such as transfu-
sions, on which many patients with haematological
malignancies depend [23].
Inter-disciplinary electronic communication was con-
sidered crucially important by participants, yet was re-
stricted by the IT systems available to practitioners
within their workplace, some of which facilitated infor-
mation sharing whilst others did not. A recent UK re-
port concluded that failings in communication within
and between palliative care teams in primary and sec-
ondary care was a major contributor to inadequate ser-
vice provision [45]. Within England, a novel unified
clinical record (the Electronic Palliative Care Coordin-
ation Systems - EPaCCS) is currently being implemented
to address this deficit. This process has not been without
challenge [46] and the impact EPaCCS has on future ser-
vice delivery will be of interest.
The importance of mutual understanding of roles has
been identified in a UK interview study that explored
haematologists’ views about collaboration with palliative
care services, along with the need for consistent and
flexible service provision [23]. In our own study, co-
location of services was considered an important means
of promoting more integrated working patterns, through
frequent opportunities for informal contact between cli-
nicians that contributed to relationship building. Two
non-UK qualitative studies examining barriers to SPC
referral from the haematologists’ and palliative care spe-
cialists’ perspectives also show clear overlap with our
findings, with difficulties identifying the end of life phase
noted as a particular barrier to SPC referral [22, 26].
Interestingly, the strong patient-clinician relationship,
perceived as reflective of quality care by some [47], was
considered a barrier to the initiation of timely end of life
discussions by others [26].
A growing body of international quantitative evidence
now exists, particularly from the US, about the provision
of palliative care for patients with haematological malig-
nancies. These studies, conducted with haematologists
and oncologists, also note concerns about the lack of
blood transfusion provision within hospices and com-
ment on inadequate awareness about the role of pallia-
tive care specialists [24, 48, 49]. More generally, a UK
study including patients with other cancers also reported
resistance to SPC and hospice referral due to the nega-
tive connotations of these services [50].
Perceptions of our interviewees about palliative care
referral and the factors influencing this largely mirror
those described in studies seeking to understand
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haematologists’ perspectives. This implies a degree of
shared awareness across specialisms regarding the
uniqueness of blood cancers and the issues differentiat-
ing patterns of care in these diseases from those of other
cancers. It is likely that this mutual understanding will
mediate future changes in practice that will facilitate im-
proved patient care.
One strength of our study is that interviewees worked
within differing SPC settings, thereby increasing the
breadth of the findings. Closely matching reports from
individuals working in different areas enhance the cred-
ibility of the results. Qualitative methods are suited to
exploration of phenomena about which little is known
[28] and the aim of purposeful sampling is to select ‘key
informants’ who can provide rich description of the phe-
nomena being studied. Our study sample yielded data
that provide new insights into an important but under-
researched area and sensitize readers to new ways of
thinking. Representativeness is not usually a key aspir-
ation in qualitative research, which has implications for
the generalizability of findings. Instead of using the term
‘generalizability’, it is more useful to talk about the ‘trans-
ferability’ of findings in relation to their relevance for
understanding similar issues and processes [31]. Ex-
trapolation of findings should take into account any
study-specific contextual factors (e.g. health-care infra-
structure; universal health-care coverage etc.) that may
limit transferability [51].
Conclusion
A range of barriers and facilitators were identified that
were said to influence the likelihood of SPC referral,
some of which related to the organisation and delivery
of SPC services, so were amenable to change, and others
relating to the complex and unique characteristics and
pathways of haematological cancers. Collaboration be-
tween haematology and palliative care specialists was
considered beneficial and desirable, and was said to be
increasing. Further research is needed to assess the ex-
tent to which palliative care is provided by haematology
doctors and nurses and other generalists and ways in
which uncertainty could be used as a trigger, rather than
a barrier, to referral.
Abbreviations
EPaCCS: Electronic Palliative Care Coordination Systems; GP: General
Practitioner; HMRN: Haematological Malignancy Research Network;
SPC: Specialist Palliative Care; UK: United Kingdom; US: United States
Acknowledgements
The authors are grateful to the palliative care specialists who took part in the
study, David Brown the project steering group lay member and Ruth Hart
who checked transcript coding.
Competing interests
The authors declare that they have no competing interests.
Funding
This work was supported by the Marie Curie Research Grants Scheme (Grant
Reference: C38860/A12554). The Haematological Malignancy Research
Network is funded by Bloodwise (Grant reference: 15037).
Availability of data and materials
All data and materials relating to this research are from the Haematological
Malignancy Research Network and are archived and maintained by the first
and last author, according to organisational and ethical regulations. Data are
not publicly available due to the risk of participant identification from
specific contexts revealed when reading entire transcripts and due to the
terms and conditions regarding the release of data to third parties upon
which ethical approvals for this study were contingent. Reasonable requests
for further information relating to this data can be made to the
corresponding author.
Authors’ contributions
DH, ER, AS, AG and MH designed the study. DH recruited study participants
and conducted interviews. Transcripts were coded and analysed by DM with
ongoing discussion/input from DH. DM wrote the first draft of the
manuscript. DH, ER, AS revised the manuscript. MH, AG, RP, and MJ
commented on the clinical aspects of the study. All authors approved the
final version.
Consent for publication
Not applicable.
Ethics approval and consent to participate
This study has NHS ethical approval (Yorkshire and the Humber Research
Ethics Committee: 11/YH/0306). All participants were given verbal and
written information about the study and their involvement. Informed written
consent was sought from individuals prior to interview and assurances given
concerning confidentiality and anonymity. Participants were informed that
they could withdraw from the study at any time.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Epidemiology & Cancer Statistics Group, University of York, York YO10 5DD,
UK. 2Department of Palliative Care, York Hospital, York YO31 8HE, UK.
3Wolfson Palliative Care Research Centre, University of Hull, Hull HU6 7RX,
UK. 4Queen’s Centre for Oncology and Haematology, Castle Hill Hospital,
Cottingham HU16 5JQ, UK. 5Department of Haematology, York Hospital, York
YO31 8HE, UK.
Received: 15 November 2017 Accepted: 13 February 2018
References
1. Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of
haematological malignancy by sub-type: a report from the Haematological
malignancy research network. Br J Cancer. 2011;105:1684–92.
2. Smith A, Crouch S, Lax S, Li J, Painter D, Howell D, et al. Lymphoma
incidence, survival and prevalence 2004–2014: sub-type analyses from the
UK’s Haematological malignancy research network. Br J Cancer. 2015;112:
1575–84.
3. Roman E, Smith A, Appleton S, Crouch S, Kelly R, Kinsey S, et al. Myeloid
malignancies in the real-world: occurrence, progression and survival in the UK’s
population-based Haematological malignancy research network 2004–15.
Cancer Epidemiol. 2016;42:186–98.
4. Manitta V, Zordan R, Cole-Sinclair M, Nandurkar H, Philip J. The symptom
burden of patients with hematological malignancy: a cross-sectional
observational study. J Pain Symptom Manag. 2011;42:432–42.
5. Zimmermann C, Yuen D, Mischitelle A, Minden MD, Brandwein JM,
Schimmer A, et al. Symptom burden and supportive care in patients with
acute leukemia. Leuk Res. 2013;37:731–6.
6. Swash B, Hulbert-Williams N, Bramwell R. Unmet psychosocial needs in
haematological cancer: a systematic review. Support Care Cancer. 2014;22:
1131–41.
McCaughan et al. BMC Palliative Care  (2018) 17:33 Page 10 of 11
7. LeBlanc TW, Smith JM, Currow DC. Symptom burden of haematological
malignancies as death approaches in a community palliative care service: a
retrospective cohort study of a consecutive case series. Lancet Haematol.
2015;2(8):e334.
8. Button EB, Gavin NC, Keogh SJ. Exploring palliative care provision for
recipients of allogeneic hematopoietic stem cell transplantation who
relapsed. Oncol Nurs Forum. 2014;41:370–81.
9. Shirai Y, Miyashita M, Kawa M, Motokura T, Sano F, Fukuda T, et al. Evaluation
of care for leukemia and lymphoma patients during their last hospitalization
from the perspective of the bereaved family. Leuk Res. 2016;47:93–9.
10. Zimmermann C, Swami N, Krzyzanowska M, Hannon B, Leighl N, Oza A,
et al. Early palliative care for patients with advanced cancer: a cluster-
randomised controlled trial. Lancet. 2014;383:1721–30.
11. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al.
Early palliative Care for Patients with metastatic non–small-cell lung cancer.
N Engl J Med. 2010;363:733–42.
12. WHO World Health Assembly. Strengthening of palliative care as a
component of integrated treatment within the continuum of care. 134th
session of the World Health Assembly. 2014: Accessed 31 Jan 2018: http://
apps.who.int/gb/ebwha/pdf_files/WHA67/A67_31-en.pdf.
13. Ferrell BR, Temel JS, Temin S, Alesi ER, Balboni TA, Basch EM, et al.
Integration of palliative care into standard oncology care: American Society
of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017;35:
96–112.
14. LeBlanc TW, El-Jawahri A. When and why should patients with hematologic
malignancies see a palliative care specialist? Hematology Am Soc Hematol
Educ Program. 2015;2015:471–8.
15. Howell DA, Shellens R, Roman E, Garry AC, Patmore R, Howard MR.
Haematological malignancy: are patients appropriately referred for specialist
palliative and hospice care? A systematic review and meta-analysis of
published data. Palliat Med. 2011;25:630–41.
16. Hui D, Kim S-H, Kwon JH, Tanco KC, Zhang T, Kang JH, et al. Access to
palliative care among patients treated at a Comprehensive Cancer Center.
Oncologist. 2012;17:1574–80.
17. Odejide OO, Cronin AM, Earle CC, LaCasce AS, Abel GA. Hospice Use
Among Patients With Lymphoma: Impact of Disease Aggressiveness and
Curability. J Natl Cancer Inst. 2015;108:pii djv280.
18. Adsersen M, Thygesen LC, Jensen AB, Neergaard MA, Sjøgren P, Groenvold
M. Is admittance to specialised palliative care among cancer patients related
to sex, age and cancer diagnosis? A nation-wide study from the Danish
palliative care database (DPD). BMC Palliat Care. 2017;16:21.
19. Sexauer A, Cheng MJ, Knight L, Riley AW, King L, Smith TJ. Patterns of
hospice use in patients dying from hematologic malignancies. J Palliat Med.
2014;17:195–9.
20. LeBlanc TW, Abernethy AP, Casarett DJ. What is different about patients
with hematologic malignancies? A retrospective cohort study of cancer
patients referred to a hospice research network. J Pain Symptom Manag.
2015;49:505–12.
21. Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ.
Aggressiveness of cancer care near the end of life: is it a quality-of-care
issue? J Clin Oncol. 2008;26:3860–6.
22. Morikawa M, Shirai Y, Ochiai R, Miyagawa K. Barriers to the collaboration
between hematologists and palliative care teams on relapse or refractory
leukemia and malignant lymphoma patients’ care: a qualitative study. Am J
Hosp Palliat Care. 2016;33:977–84.
23. Wright B, Forbes K. Haematologists’ perceptions of palliative care and
specialist palliative care referral: a qualitative study. BMJ Support Palliat Care.
2014; https://doi.org/10.1136%2Fbmjspcare-2014-000689
24. LeBlanc TW, O’Donnell JD, Crowley-Matoka M, Rabow MW, Smith CB, White
DB, et al. Perceptions of palliative care among hematologic malignancy
specialists: a mixed-methods study. J Oncol Pract. 2015;11:e230–8.
25. LeBlanc TW, Roeland EJ, El-Jawahri A. Early palliative Care for Patients with
hematologic malignancies: is it really so difficult to achieve? Curr Hematol
Malig Rep. 2017;12:300–8.
26. Odejide OO, Coronado DYS, Watts CD, Wright AA, Abel GA. End-of-life Care
for Blood Cancers: a series of focus groups with hematologic oncologists.
J Oncol Pract. 2014;10:e396–403.
27. Moreno-Alonso D, Porta-Sales J, Monforte-Royo C, Trelis-Navarro J, Sureda-
Balarí A. Fernández de Sevilla-Ribosa a. Palliative care in patients with
haematological neoplasms: an integrative systematic review. Palliat Med.
2018;32:79–105.
28. Mays M, Pope C, editors. Qualitative research in health care. London: BMJ
Books; 2006.
29. Baker S, Edwards R. How many qualitative interviews in enough? Expert
voices and early career reflections on sampling and cases in qualitative
research. Review paper. UK: National Centre for Research Methods,
University of Southampton; 2012.
30. Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework
method for the analysis of qualitative data in multi-disciplinary health
research. BMC Med Res Methodol. 2013;13:117.
31. Lincoln YS, Guba EG. Naturalistic inquiry. Newbury Park, CA: Sage
Publications; 1985.
32. Barbour RS. Checklists for improving rigour in qualitative research: a case of
the tail wagging the dog? BMJ. 2001;322:1115–7.
33. Noble H, Smith J. Issues of validity and reliability in qualitative research. Evid
Based Nurs. 2015;18:34–5.
34. King N, Horrocks C. Interviews in qualitative research. London: Sage; 2010.
35. NHS England. Specialist level palliative care: information for commissioners
2016: Accessed 13 Nov 2017: https://www.england.nhs.uk/wp-content/
uploads/2016/04/speclst-palliatv-care-comms-guid.pdf.
36. McIlvennan CK, Allen LA. Palliative care in patients with heart failure. BMJ.
2016;353:i1010.
37. Braun LT, Grady KL, Kutner JS, Adler E, Berlinger N, Boss R, et al. Palliative
care and cardiovascular disease and stroke: a policy statement from the
American Heart Association/American Stroke Association. Circulation. 2016;
134:e198–225.
38. Button E, Chan RJ, Chambers S, Butler J, Yates P. A systematic review of
prognostic factors at the end of life for people with a hematological
malignancy. BMC Cancer. 2017;17:213.
39. LeBlanc TW. Palliative care and hematologic malignancies: old dog, new
tricks? J Oncol Pract. 2014;10:e404–7.
40. Porta-Sales J, Guerrero-Torrelles M, Moreno-Alonso D, Sarrà-Escarré J, Clapés-
Puig V, Trelis-Navarro J, et al. Is early palliative care feasible in patients with
multiple myeloma? J Pain Symptom Manag. 2017;54:692–700.
41. Boucher NA, Johnson KS, LeBlanc TW. Acute leukemia patients’ needs:
qualitative findings and opportunities for early palliative care. J Pain
Symptom Manag. 2017;55:433–9.
42. McGrath P. Qualitative findings on the experience of end-of-life care for
hematological malignancies. Am J Hosp Palliat Care. 2002;19:103–11.
43. WHO Definition of Palliative Care. World Health Organisation. Accessed 2
Feb 2018: http://www.who.int/cancer/palliative/definition/en/.
44. McGrath P, Holewa H. Haematology and palliative care: towards an
integrated practice. International program of psycho-social Health Research
(IPP-SHR). Central Queensland University, Australia Accessed 2 Feb 2018:
https://issuu.com/hholewa/docs/haempc.
45. Parliamentary and Health Service Ombudsman (PHSO). Dying without
dignity. 2015: Accessed 3 Aug 2017: https://www.ombudsman.org.uk/
publications/dying-without-dignity-0.
46. Petrova M, Riley J, Abel J, Barclay S. Crash course in EPaCCS (electronic
palliative care coordination systems): 8 years of successes and failures in
patient data sharing to learn from. BMJ Support Palliat Care. 2016; https://
doi.org/10.1136%2Fbmjspcare-2015-001059
47. McCaughan D, Roman E, Smith AG, Garry A, Johnson M, Patmore R, et al.
Determinants of hospital death in haematological cancers: findings from a
qualitative study. BMJ Support Palliat Care. 2017; https://doi.org/10.
1136%2Fbmjspcare-2016-001289
48. Epstein AS, Goldberg GR, Meier DE. Palliative care and hematologic
oncology: the promise of collaboration. Blood Rev. 2012;26:233–9.
49. Odejide OO, Cronin AM, Earle CC, Tulsky JA, Abel GA. Why are patients with
blood cancers more likely to die without hospice? Cancer. 2017;123:3377–84.
50. Zimmermann C, Swami N, Krzyzanowska M, Leighl N, Rydall A, Rodin G,
et al. Perceptions of palliative care among patients with advanced cancer
and their caregivers. CMAJ. 2016;188:E217–27.
51. Green J, Thorogood N. Qualitative methods for Health Research. 3rd ed.
London: Sage; 2014.
McCaughan et al. BMC Palliative Care  (2018) 17:33 Page 11 of 11
